Clinical Scorecard: Oral spironolactone may hold edge in female acne
At a Glance
| Category | Detail |
|---|---|
| Condition | Adult female acne; the review compares oral and topical spironolactone. |
| Key Mechanisms | The source reports clinical efficacy and systemic-exposure findings; it does not describe a specific mechanism of action. |
| Target Population | Primarily adult women with acne; some topical studies included mixed-sex cohorts or male volunteers. |
| Care Setting | Not specified in the source. |
Key Highlights
- Oral spironolactone had stronger supporting evidence than topical formulations for adult female acne, although efficacy could not be compared directly across studies.
- In the 410-participant SAFA trial, acne-specific quality-of-life symptom scores favored spironolactone at 12 and 24 weeks; investigator-assessed treatment success at 12 weeks was 19% versus 6% with placebo. The primary-outcome difference at 12 weeks did not reach the 2-point difference the trial was powered to detect.
- Topical studies reported lesion reductions, but evidence was limited by small samples, short follow-up, varied formulations and outcomes, and indirect applicability to adult women.
- Reported oral adverse effects included menstrual irregularities and breast tenderness. Hyperkalemia was more frequent in women aged 46–65 years than in those aged 18–45 years in one retrospective study.
- The review searched two databases, largely restricted eligibility to English-language publications, did not conduct a formal risk-of-bias assessment, and did not perform a meta-analysis.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Clinical Best Practices
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
